Business

Despite pressure, Biogen’s Alzheimer’s disease drug is still likely to be a big hit

US taxpayers are set to bear most of Biogen’s new treatments for Alzheimer’s disease, and investors are nervous.

The Food and Drug Administration approved Aduhelm earlier this month, despite serious controversy. Some prominent experts have blown up regulators to allow the sale of ineffective drugs.

Those arguments did not convince the FDA, but Spats raises questions Medicare is the payment method for medicinesThe annual sticker price before rebates or discounts is $ 56,000. Investors suspect that Aduhelm will not live up to its blockbuster expectations. Biogen’s share price has risen 30% in the past month, but has fallen nearly 20% since June 10.

There are good reasons for skepticism. Medicare usually pays for all approved drugs, but officials from the Biden administration said the government “can’t afford to treat this as a normal business.” And the price of Aduhelm is just one item in the list of costs required for the patient to receive it. Others include a parade of brain imaging, injection costs, and a doctor’s consultation to assess disease progression.

In addition, Biogen can face competition sooner than Wall Street expected.Rival pharmaceutical company Eli Lilly said it plans to apply last week Regulatory approval for unique treatment of Alzheimer’s diseaseThe drug could probably hit the market soon at the end of next year. Lily’s donanemab is similar to Aduhelm, but may be more effective.

Despite pressure, Biogen’s Alzheimer’s disease drug is still likely to be a big hit

Source link Despite pressure, Biogen’s Alzheimer’s disease drug is still likely to be a big hit

Back to top button